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Abstract
Background: Sporulation of Clostridium difficile during infection and persistence of spores within the gut could
partly explain treatment failures and recurrence. However, the influence of antibiotics on sporulation is unclear. The
objective of our study was to evaluate the impact of ciprofloxacin, metronidazole, piperacillin/tazobactam,
tigecycline, and vancomycin on C. difficile sporulation in vitro.
Methods: The reference strains ATCC 9689, 630, VPI 10463, and seven other clinical isolates of C. difficile were used,
including three epidemic NAP1/027 isolates. Minimum inhibitory concentrations (MIC) were determined and
sporulation was assessed after growth in the absence or presence of ≤0.5x MIC concentrations of each antibiotic.
Results: All strains were sensitive to the antibiotics tested, except ribotype 027 isolates that were resistant to
ciprofloxacin (MIC = 128 mg/L). Metronidazole and vancomycin generally did not significantly affect spore
production in C. difficile, although vancomycin slightly affected sporulation of a few isolates. Ciprofloxacin inhibited
sporulation of ribotype 027 isolates mainly. Interestingly, sub-MIC concentrations of piperacillin/tazobactam reduced
spore formation in several isolates. However, the most striking observation was made with tigecycline, with an
important reduction of spore formation in most isolates.
Conclusions: The capacity of C. difficile to sporulate can be significantly affected by certain antibiotics. The reduced
sporulation observed with tigecycline and piperacillin/tazobactam might explain why these antibiotics are generally
associated with lower risk of C. difficile infections. In addition, the inhibition of sporulation might partly explain the
apparent efficacy of tigecycline for treatment of patients with recurrent infection.
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Background
Several outbreaks caused by Clostridium difficile have
been reported worldwide over the last decade. The
emergence of an epidemic strain of C. difficile, NAP1/
027, was associated with more severe disease, and a
higher recurrence rate [1,2]. This rate ranges from 8-
50% and the likelihood of recurrence increases with
the number of CDI episodes [3,4], which makes the
management of recurrence challenging [5-7]. Disruption
of the normal intestinal microbiota is associated with
a higher risk of CDI and antibiotics are generally the
triggering factor [8-10]. Prolonged disruption of the
intestinal microbiota by antibiotic treatment may also
increase patients’ susceptibility to recurrent CDI. Recur-
rence can be caused by the persistence of C. difficile in
the intestinal tract, or re-infection by the same or a dif-
ferent strain [5-7]. The same strain has been isolated in
50-90% of recurrence cases, which indicates that persist-
ence of C. difficile spores in the intestinal tract of the
patient is possibly a prerequisite to this condition [4,11].
Spores of C. difficile are highly resistant to harsh envi-
ronments and household disinfectants and are likely
responsible for efficient dissemination of C. difficile in
hospital settings [12,13]. In addition, they are resistant to
all known antibiotics including metronidazole (MTZ) and
vancomycin (VAN) [14]. Some studies suggested that epi-
demic strains of C. difficile sporulate more efficiently and
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to higher levels than non epidemic strains, which might ex-
plain why epidemic strains disseminate easily in hospitals
[12,13], but this hypothesis is a matter of debate [15,16].
Early upon infection, C. difficile is capable of forming
spores, as suggested by the induction of sporulation-
associated gene transcription as soon as 8 h post-infection
[17]. However, the factors that affect this process are not
well known. Previous reports suggested that sub-inhi-
bitory (sub-MIC) concentrations of certain antibiotics can
trigger C. difficile sporulation in vitro [18,19]. More
recently, sub-MIC concentrations of fidaxomicin were
shown to inhibit spore formation and toxin production in
C. difficile [20,21]. This suggests that antibiotics can
potentially influence the number of spores that are formed
during CDI and as such, directly impact the treatment
outcome and the risk of recurrence.
The objective of this study was to determine the
impact of sub-MIC concentrations of 5 antibiotics on
sporulation of 10 different isolates of C. difficile in vitro.
For this, we used a microscopic method to count vegeta-
tive cells and spores present within colonies growing on
agar, as well as a classical spore recovery assay after
growth and sporulation in broth cultures.
Methods
Bacterial strains and growth conditions
C. difficile reference strains ATCC 9689, ATCC 43255
(VPI 10463) and 630 were used along with 7 other clin-
ical isolates that were purified from feces after alcohol
shock and growth on CDMN selective agar (Clostridium
difficile agar base supplemented with moxalactam and
norfloxacin) (Oxoid, Canada). Feces were obtained from
patients recruited during a non-outbreak period at the
Centre Hospitalier Universitaire de Sherbrooke in the
province of Quebec, Canada. The institutional review
board of the CHUS had approved our study protocol
and informed consent was obtained from all patients.
The identity of presumptive C. difficile colonies was
confirmed by amplifying by PCR the triose phosphate
isomerase gene (tpi) of C. difficile, as described before
[16,22]. C. difficile was grown at 37°C in an anaerobic
chamber (Coy Laboratories, USA). Bacteria were rou-
tinely grown in brain heart infusion broth (BHI) (Difco),
BHI supplemented with 0.1% taurocholate and 1 mM
glycine (BHI-tag) to favor spore germination, or in tryp-
tose yeast extract broth or agar (TY) (3% tryptose
(Oxoid, Canada), 2% yeast extract (BioShop, Canada)).
All media were pre-reduced overnight prior to use.
Molecular typing
Genomic DNA was extracted from 1.5 mL overnight
cultures in BHI broth using the Bacteria genomicPrep kit
(GE Healthcare, Canada). PCR ribotyping, tandem repeat
sequence typing (TRST), detection of tcdA, tcdB, cdtA and
cdtB, as well as sequencing of the tcdC gene was done as
described before using PCR primers listed elsewhere [16].
MIC determination
Minimum inhibitory concentrations (MIC) for MTZ
(Sigma), VAN (Sigma), ciprofloxacin (CIP) (Sigma),
piperacillin/tazobactam (TZP) (Sandoz), and tigecycline
(TIGE) (Pfizer) were determined by the agar dilution
method and interpreted according to the Clinical and
Laboratory Standards Institute (CLSI) guidelines [23].
Briefly, TY agar plates were used for susceptibility testing
in order to mimic the conditions of the sporulation
assays. A 10-μl sample from a log-phase culture of C.
difficile (optical density at 600 nm = 0.5) was streaked
over TY agar plates containing doubling dilutions of
each antibiotic. Plates were incubated under anaerobic
conditions for 48 h and MIC values were determined as
the antibiotic concentration where colonies did not grow.
Evaluation of spore formation
Sporulation on agar plates
For time course assays, a 10-μl sample from a log-phase
C. difficile culture grown in BHI was streaked onto TY
agar plates with or without 0.5x MIC of each antibiotic.
Bacteria were then grown for 48 h and 96 h and 10
colonies of similar size were picked with a sterile swab
and homogenized in 0.5 mL of 0.1x BHI broth. Note
that log-phase BHI pre-cultures contain only very few
spores (our unpublished observation) so using this type
of inoculum greatly limits carrying over spores onto TY
plates when setting up the sporulation assay. Still, in the
eventuality that a few spores were carried over and inoc-
ulated onto TY plates, their number was negligible since
we further analyzed growing colonies, i.e. bacteria that
grew from isolated vegetative cells or spores that have
germinated and outgrown. It is also important to note
that we ensured that colonies growing in the presence of
0.5x MIC antibiotic grew to a size similar to those on
the control plates without antibiotic to avoid any bias
due to growth defects. The number of spores and the
percentage of sporulation were calculated either after
recovery of viable spores and bacteria on agar, or by a
microscopic method (see below).
Sporulation in liquid broth cultures
Spore formation was also evaluated in broth cultures.
For this, log-phase cultures in BHI were inoculated in
TY broth at an initial density of 1×106 colony-forming
units/mL (CFU/mL). Bacteria were either grown in the
absence (No ATB control) or presence of 0.5x MIC anti-
biotics. After 48 h or 96 h of culture, samples were ana-
lyzed for the presence of vegetative cells and spores, by
either recovering viable spores and bacteria on agar, or
using a microscopic method, as described below.
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Microscopic method to evaluate spore formation
A 15-μL sample from a bacterial suspension prepared
from colonies grown on agar or bacteria grown in broth
cultures was deposited onto microscope slides, dried
at room temperature and then fixed at 80°C for 5 min.
Staining with safranin was performed before micro-
scopic observation using an Olympus IX-81 microscope
equipped with a Retiga 2000R monochrome cooled CCD
camera. Images from 5 different fields were taken on
each slide and were processed with Metamorph v5 (Mo-
lecular Devices, USA) and ImageJ v1.44o (National Insti-
tute of Health, USA). Vegetative cells and spores were
counted and the mean ± standard error of the mean
(SEM) of 3 independent biological replicates (3 × 5
images) was plotted. The percentage of spores in each
image was also calculated as follows: [Nspores / (Nspores +
Nvegetative cells)]*100. For concentration range assays, the
same procedure described above was used except that
the percentage of spores was determined at 48 h only
and the antibiotic concentrations corresponded to 0.5x,
0.25x, 0.125x and 0.0625x MIC.
Conventional spore recovery assay to evaluate sporulation
Bacterial suspensions prepared from colonies grown on
agar or bacteria grown in broth cultures were serially
diluted and plated on BHI-tag agar to determine total vi-
able counts. In parallel, aliquots from these suspensions
were treated for 1 h with ethanol (50% final concentra-
tion) and then plated on BHI-tag agar to count only
spores [16]. The values of CFU/mL from three inde-
pendent experiments were plotted and the number of
vegetative cells was calculated by subtracting the num-
ber of spores from the total count. Controls were also
done in which untreated samples were plated directly on
BHI without taurocholic acid and glycine, to monitor
viability of vegetative cells only (spores germinate very
poorly on BHI alone).
Statistical analysis of the data
Statistical analysis of the data was done using GraphPad
Prism v6.0c (California, USA). For sporulation assays
determined with the microscopic method, the mean
percent sporulation in the presence of antibiotic from 3
biological replicates was compared with the correspond-
ing control without antibiotic. The same method was
used to calculate spore formation on agar after ethanol
shock and spore recovery on agar. For sporulation assays
in broth, the total counts of vegetative cells and spores
were compared (in CFU/mL, mean of 3 biological repli-
cates). One-way analysis of variance (ANOVA) was
performed in Prism to compare each condition with the
corresponding controls without antibiotic. Means were
considered significantly different when p < 0.05.
Results
Strain characteristics
The C. difficile isolates selected for sporulation assays were
all toxigenic and carried the tcdA and tcdB genes (data not
shown). Overall, the isolates represented 6 different PCR
ribotypes and 7 TRST types (Table 1). Three isolates
(CD274, CD386 and CD390) were ribotype and TRST
type 027, had the characteristic 18-bp and 1-bp deletions
in the tcdC gene, and were binary toxin-positive. Hence,
these isolates correspond to the epidemic strain that
caused outbreaks in Canada recently. Isolates CD385 and
CD398 (ribotype 018) were also binary toxin-positive, but
they had a non-deleted tcdC (Table 1). CD392 and CD400
had the same ribotype (014), but were of different TRST
types (014 and 065 respectively).
Antibiotic susceptibility testing
Susceptibility to antibiotics was determined for all strains
and results are summarized in Table 2. According to the
CLSI guidelines, all isolates were susceptible to the antibi-
otics tested, except the three ribotype 027 isolates CD274,
CD386 and CD390 that were resistant to CIP [23].
Sporulation assays
The capacity of C. difficile isolates to sporulate in the
presence of sub-MIC concentrations of antibiotic was
assessed. Figure 1 is a stacked bar graph showing the
mean number of vegetative cells (light grey) and spores
(dark grey) counted by microscopy after 48 h and 96 h
of growth in the absence or presence of 0.5x MIC of
tigecycline (TIGE), piperacilin/tazobactam (TZP), cipro-
floxacin (CIP), vancomycin (VAN), or metronidazole
(MTZ). The % spores for each antibiotic treatment was
determined and then compared with the % spores of the
Table 1 Characteristics of the selected strains
Strain number PCR ribotypea TRSTb tcdCc Binary toxind
ATCC 9689 001 001 - -
630 012 012 - -
VPI 10463
(ATCC 43255)
037 058 - -
CD274 027 027 + +
CD385 018 019 - +
CD386 027 027 + +
CD390 027 027 + +
CD392 014 014 - -
CD398 018 019 - +
CD400 014 065 - -
aRibotypes were attributed according to reference strains, except ribotype 018
that was assigned arbitrarily according to our internal database.
bType numbers correspond to those published by Zaiss et al., [24].
cPresence (+) or absence (−) of the characteristic 18-bp deletion, and 1-bp
deletion at nucleotide 117.
dPresence (+) or absence (−) of the binary toxin genes cdtA and cdtB.
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untreated control using ANOVA. To avoid overcrowding
the graph, the % values are indicated only for the controls
and the conditions where the % spores was significantly
different from the controls. In the absence of antibiotic,
most strains produced between ~10-35% spores at 48 h
and ~25-65% at 96 h. One exception was strain ATCC
9689 that produced very few spores, even after 96 h of
growth (only 2.5%). Statistical analysis of the data revealed
that in the presence of 0.5x MIC of MTZ, sporulation was
not significantly affected, except for strain CD385 that
produced less spores at 96 h (44.3% vs 59.9% for the
control). In the case of VAN, most isolates produced similar
amounts of spores compared to the control group, except 4
isolates for which 0.5x MIC of VAN slightly increased the
number of spores produced either after 48 h (CD398: 27.3
vs 15.6%) or 96 h (ATCC 9689: 6.8 vs 2.5%; CD274: 42.5 vs
35.4%; CD386: 43.5 vs 30.1%) but values were in the same
range.
In the presence of 0.5x MIC of CIP, spore formation was
significantly lower for 6/10 isolates (VPI 10463, CD274,
CD385, CD386, CD390 and CD398). Interestingly the in-
hibition of sporulation by CIP was more pronounced at
both 48 h and 96 h with strains CD274, CD386 and
CD390, three ribotype 027 isolates that were resistant to
CIP (Table 2). The most striking results however were
observed in the presence of 0.5x MIC of TIGE and TZP,
which strongly reduced spore formation in 9/10 isolates at
both time points (except with TZP for CD400 at 48 h and
VPI 10463 at 96 h). With these antibiotics, spore counts
were very low (often <1%) in most samples as opposed to
the controls or with other antibiotics for which hundreds
of spores were counted (Figure 1).
In order to confirm the impact of antibiotics on sporula-
tion and to monitor for viability of spores and vegetative
cells, we performed a classical spore recovery experiment
on a subset of isolates and conditions. For these assays, we
included TIGE and TZP that had the strongest inhibitory
effect on sporulation, and VAN that had little effect on
spore formation, except with a few isolates. We selected a
subset of 4 isolates of different TRST type including
CD386, a ribotype 027. Colonies obtained on agar after
48 h of growth were treated with ethanol to kill vegetative
cells and then serially diluted and plated on BHI-tag agar
to recover spores. Untreated samples were run in parallel
to recover total bacteria (spores + vegetative cells). The
calculated % spores are indicated as boxed values above
the corresponding bars in Figure 1. The values of % spores
in the controls without antibiotic and with VAN were
slightly different from the values obtained in microscopy,
but they were in the same range. However, the inhibition
of sporulation by TIGE and TZP that was observed in mi-
croscopy was even more evident and stronger after recov-
ery of spores and bacteria on agar, thus confirming that
TIGE and TZP really inhibit spore formation and that
vegetative cells observed in microscopy were viable
(counts were in the range of 107-109 CFU/mL).
We also monitored the accumulation of spores over time
in liquid broth in the presence or absence of antibiotics,
using the same subset of isolates and TIGE and VAN for
comparison. Bacteria were inoculated in TY broth and
allowed to grow and sporulate for 48 h. Aliquots were re-
moved, a fraction of which was treated with ethanol to kill
vegetative cells, and serial dilutions were plated on BHI-tag
agar. We also plated a series of samples on BHI alone to
observe growth of vegetative cells only (spores germinate
very poorly in the absence of taurocholate and glycine). As
can be seen in Figure 2, the number of vegetative cells/mL
that formed colonies after 48 h (calculated by subtracting
the number of spores from the total count) was not signifi-
cantly different in the absence or in the presence of 0.5x
MIC of TIGE or VAN, thus ruling out a possible inhibitory
effect of TIGE on vegetative growth. The only exception
was seen with VAN and CD400 where a slightly lower
number of vegetative cells could be recovered after 48 h.
On average, ~105 - 107 spores/mL formed in the absence of
antibiotic, but TIGE significantly reduced the number of
spores/mL by at least 2–3 orders of magnitude in all iso-
lates. The values of % spores calculated from the CFU/mL
are indicated above the corresponding groups in Figure 2.
Statistical analysis of the data using ANOVA suggests that
the reduction in spore formation was not significant with
CD398 and CD400 (p > 0.05), but a clear trend towards re-
duced sporulation was evident with CD398 and to a lesser
extent CD400. With VAN, the amount of spores/mL was
similar or slightly higher (though not statistically signifi-
cant) than the control without antibiotic. We also used in
parallel the microscopic method to determine the % spore
after sporulation in broth culture. The values are indicated
in the boxes below each corresponding graph. The number
of spores/mL was low after 48 h of growth compared to the
sporulation assays on agar, so we continued the incubation
Table 2 Antibiotic susceptibility results for the selected strains
MIC (mg/L)
Straina CIP MTZ TZP VAN TIGE
CD211 4 0.1 6 1 0.016
630 4 0.1 16 1 0.032
VPI 10463 8 0.2 12 1 0.032
CD274* 128 0.2 12 1 0.016
CD385 4 0.1 16 1 0.032
CD386* 128 0.1 16 1 0.016
CD390* 128 0.2 12 1 0.016
CD392 8 0.2 16 1 0.016
CD398 4 0.1 12 1 0.016
CD400 8 0.1 16 1 0.016
aThe *indicates a ribotype 027 isolate.
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(See figure on previous page.)
Figure 1 Stacked bar graph showing the number of vegetative cells and spores in colonies grown for 48 h and 96 h on TY agar
without antibiotics (No ATB) or with 0.5x MIC of TIGE, TZP, CIP, VAN, or MTZ. The values of spore counts (dark grey bars) are stacked on
top of the vegetative cell counts (lower light grey bars). The percentage of spores formed in the presence or absence of antibiotics was also
calculated for each condition and compared by one-way ANOVA. When the percentage of spores was significantly lower compared to the
control. For simplicity, only the % spores for the controls and the significantly different conditions are indicated above the corresponding bars.
Boxed values above some of the bars represent the % spores calculated using a spore recovery assay on agar plate after ethanol shock. Values
represent means ± standard error of the mean of 3 independent experiments (mean of 5 microscopy images/experiment). Statistical significance:
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% spores in microscopy (Time)
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% spores in microscopy (Time)
 19.9    0.1      10.2  (48h)
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% spores in microscopy (Time)
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64.2    4.2(****)   46.3(**)  (96h)
1.5% 13.6%
0.4%
No ATB TIGE VAN No ATB TIGE VAN
Figure 2 Vegetative cells and spores growing on agar after 48 h of growth in liquid TY broth containing 0.5x MIC of TIGE (orange
dots) or VAN (blue dots). No ATB = control without antibiotic (grey dots). Dots represent the Log10 counts from 3 independent experiments
(each done in duplicate). The dashed line indicates the limit of detection in our assay, which was 40 CFU/mL. When the spore count was below
the limit of detection, the value was arbitrarily set at 40 CFU/mL. The mean values of % spores are indicated above each corresponding group for
reference. The mean spore counts in the presence of antibiotics were compared with the control without antibiotics by one-way ANOVA. The
boxes below each graph represent the mean % spores determined after 48 h and 96 h using the microscopic method. The values were compared
by ANOVA. Statistical significance: * = p < 0.05; ** = p < 0.01; *** = p < 0.001; **** = p < 0.0001.
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up to 96 h. The calculated % spores reached values similar
to those in the agar assays at 96 h, and the inhibition of
sporulation by TIGE was here also very strong and signifi-
cant. The % spores with VAN were also lower (p < 0.01)
with CD392 and CD400, but the inhibition in spore forma-
tion was at least 10 times stronger with TIGE. Note that we
also confirmed the inhibitory effect of TZP on sporulation
in broth assays as well (data not shown). Therefore, these
results in broth cultures confirmed those obtained on agar,
even if values did vary slightly due to the different growth
conditions that might affect the dynamics of sporulation.
To determine if the inhibition of sporulation was
dependent on the concentration of antibiotic, we per-
formed concentration range assays on three isolates of
different ribotype, including a ribotype 027 (CD386) and
VPI 10463, a well-known high toxin-producing strain
used in various studies including in vivo assays in ani-
mals [25,26]. We inoculated bacteria on agar plates con-
taining antibiotics in the range of 0.0625-0.5x MIC and
used our microscopy method to count vegetative and
sporulated cells and to calculate the % spores. The results





























































































































































5 0.5 x MIC
VAN MTZTIGE CIPTZP
Figure 3 Percentage of spores within colonies collected after 48 h of growth on TY agar containing different sub-MIC concentrations
of TIGE, TZP, CIP, VAN, or MTZ. No ATB = control without antibiotic. Values represent the means ± standard error of the mean of three
independent experiments. Each condition was compared to the control without antibiotics using one-way ANOVA and asterisks indicate the
means that were statistically different. Statistical significance: * = p < 0.05, ** = p < 0.01, *** = p < 0.001 and **** = p < 0.0001.
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inhibition of sporulation by TIGE with all three isolates.
With TZP, the inhibition of sporulation was observed at
all concentrations in the case of VPI 10463 and CD386,
but the inhibition did not increase proportionally to the
increasing concentrations of TZP with VPI 10463 and
CD392. In the later case, the inhibition was significant
only at 0.5x MIC. A similar trend was seen with CIP,
for which a concentration-dependent inhibition of spore
formation was observed with CD386, while some inhib-
ition was seen with VPI 10463 at 0.5x MIC. Sporulation of
CD392 was not affected by CIP, which is what we expected
since there was no difference in sporulation even at 0.5x
MIC (Figure 1). With MTZ and VAN, there was no
significant difference in the formation of spores, as also
expected from the results in Figure 1.
Discussion and conclusions
The objective of our study was to evaluate the impact of
various antibiotics on the in vitro sporulation of a set of
10 relevant isolates of C. difficile. Our results strongly
suggest that sub-MIC concentrations of TIGE, TZP, and
to some extent CIP, have inhibitory effects on sporula-
tion of most isolates. On the other hand, VAN slightly
stimulated or inhibited spore production in a few iso-
lates only and MTZ had no significant effect, except
with one isolate where we observed a slight reduction in
sporulation. Most importantly, we obtained similar re-
sults in both agar and broth sporulation assays, and
using a microscopic method as well as a conventional
spore recovery assay after ethanol shock and growth on
agar. Therefore, the inhibition of spore formation that
we observed in our study was not the consequence of a
growth defect or death of vegetative cells, or poor resist-
ance to ethanol of incompletely maturated spores. Our
data rather strongly suggest that spore formation is
significantly impaired. A recent study reported that C.
difficile strains ATCC 43255 (i.e. VPI 10463) and UK-14
sporulated to similar levels in the absence or presence of
sub-MIC of MTZ or VAN [20]. In that study, sporula-
tion was performed over 10 days in Brucella broth and
spores were counted on agar plates after heat shock. In
addition, the antibiotics were added at the end of the loga-
rithmic phase of growth and not at the time of inocula-
tion. Under these conditions, the maximum spore counts
were reached between ~24 and 96 h and remained rela-
tively stable over the rest of the experiment [20]. Two pre-
vious studies suggested that on the contrary, MTZ and
VAN strongly promoted sporulation of C. difficile when
present at sub-MIC. Ochsner reported that sporulation of
C. difficile strains ATCC 43596 and MB903 increased
from a basal level of 10% and 17% without antibiotic to
100% after 4 days of incubation in the presence of sub-
MIC concentrations of MTZ or VAN [18]. A strong
increase in sporulation of strain RMA 18386 was also
observed in the presence of sub-MIC of MTZ (from 0.8%
to 53%) [18]. In a similar study, Mathur et al. showed that
sub-MIC concentrations of MTZ and VAN also stimu-
lated sporulation of C. difficile strains ATCC 43596 and
PGI 1 to very high levels after 6 days of incubation (from
8.8-11% without antibiotic to 75-100% with antibiotic)
[19]. In the two later studies, sporulation was assessed
over 4 to 6 days on Brucella agar and the spores were
counted after ethanol shock and recovery on agar plates
[18,19]. We also observed increased sporulation in the
presence of sub-MIC concentrations of VAN, but only
with a few isolates. In addition, no difference was observed
with VAN or with MTZ with most isolates. This suggests
that depending on the strain of C. difficile under study, the
impact of antibiotics on sporulation can vary and thus, a
larger set of strains might be necessary to observe general
trends rather than effects that might be strain-specific.
The presence of TIGE at sub-MIC concentrations
strongly inhibited sporulation of 9/10 C. difficile isolates
tested and moreover, the effect was concentration-
dependent. A similar trend was also observed with TZP,
although a concentration dependence was seen with only
1/3 isolates tested. Fidaxomicin was recently found to
strongly inhibit the formation of spores of C. difficile
ATCC 43255 and UK-14 when present at sub-MIC, and
a lower transcription of sporulation-specific mRNAs was
observed in strains CD196 and UK-1 [20]. The synthe-
tic methionyl-tRNA synthetase inhibitor REP3123 was
found to strongly inhibit sporulation of C. difficile ATCC
43596, MB903 and RMA 18383 in a dose-dependent
manner when present at sub-MIC concentrations [18].
Similarly, the biaryl oxazolidinone molecule RBx11760
completely inhibited sporulation of C. difficile strains
ATCC 43596 and PGI 1 at 0.5x-MIC [19]. Together,
these studies also suggest that certain antibiotics have a
marked inhibitory effect on sporulation of C. difficile
when present at sub-MIC concentrations. In our study,
the effect of TIGE and TZP could be observed with sev-
eral isolates, thus minimizing a possible strain-specific
effect. The only isolate that did not respond like the
others was ATCC 9689, but the number of spores
formed by this strain was already very low, making it
more difficult to see inhibition of sporulation by antibi-
otics. On the contrary, VAN, TZP and MTZ tended to
increase spore formation by this isolate.
Babakhani reported that fidaxomicin affected spore
formation possibly by blocking the accumulation of
spoIIR and spoIIID mRNAs, which are expressed specif-
ically during sporulation [20]. This is thought to be due
to the anti-RNA polymerase activity of fidaxomicin, but
whether the inhibition applies to all bacterial genes or
only to sporulation genes is unknown [20]. We noted a
decrease in sporulation in the presence of CIP, especially
with ribotype 027 strains. For those particular isolates,
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higher CIP concentrations had to be incorporated into
agar plates to reach 0.5x MIC, because of their intrinsic
resistance to CIP. Thus, although growth of these strains
was not affected, high CIP concentrations seemed to
alter sporulation somehow. Whether CIP interferes with
transcription of sporulation-specific genes like fidaxomi-
cin remains to be determined, but since CIP interferes
with DNA synthesis and replication, this would not, a
priori, be logical. However, a number of studies have
shown that transcription of virulence-associated genes in
C. difficile can be affected by antibiotics that are not in-
hibitors of transcription per se. For example, Gerber
et al. observed that 0.5x MIC of MTZ, VAN, and linezo-
lid increased transcription of tcdA and tcdB toxin genes
in 4 different strains of C. difficile, including VPI 10463
[27]. Toxin gene transcription and production were also
increased in high-level CIP-resistant isolates of C. diffi-
cile, and a dose-dependent response was observed [28].
Likewise, sub-MIC concentrations of ampicillin and clin-
damycin strongly increased transcription of genes coding
for the colonization factors Cwp84 and the surface layer
protein SlpA in NAP1/027 isolates [29]. In addition,
ofloxacin and moxifloxacin increased transcription of
cwp84 and slpA, but only in ofloxacin and moxifloxacin-
resistant isolates [29]. Altogether, current data from the
literature suggest that sub-inhibitory concentrations of
certain antibiotics can affect virulence-associated pheno-
types and sporulation in resistant strains, in part via
modulation of transcription.
It is noteworthy to mention that we observed an inhib-
ition of sporulation with 3 different antibiotics that have
different modes of action: TIGE inhibits protein synthe-
sis, CIP interferes with DNA synthesis and replication,
and TZP interferes with cell wall synthesis. A possible
mechanism explaining the inhibition of sporulation is
thus rather speculative at the moment, but the fact that
REP3123 and RBx11760 are both protein synthesis in-
hibitors led Mathur to propose that the inhibitory effect
on sporulation was probably due to a general inhibition
of the spore coat protein synthesis [18,19]. This hypoth-
esis may apply to TIGE as well, which is also an inhibi-
tor of protein synthesis, but does not reconcile the
results obtained with TZP and CIP. However, as men-
tioned above, transcription of several genes can be af-
fected by antibiotics, including quinolones to which
bacteria are already resistant [29]. Of note, bacteria grew
well in the presence of sub-MIC concentrations of all
antibiotics tested in our study, suggesting that the inhib-
ition of sporulation by TZP and high CIP concentrations
was not directly linked to the growth capacity or cell
viability, as reported previously with other antibiotics
[27,29,30]. Further studies will be necessary to elucidate
the molecular mechanism by which CIP, TZP and TIGE
inhibit sporulation.
The biological significance of the inhibition of sporula-
tion by sub-inhibitory concentrations of antibiotics
in vitro remains to be determined in vivo. Although fecal
concentrations of TIGE are generally much higher than
the MIC for C. difficile (range of 3.0-14.1 μg/g feces)
[31], it is possible that sub-MIC concentrations could
occur early at the beginning, or at the very end of the
antibiotic treatment, during which period sporulation
could be affected. A recent transcriptomic analysis in
mice mono-colonized with C. difficile revealed that
transcription of sporulation-associated genes was upreg-
ulated as soon as 8 h post infection, therefore suggesting
that spores are formed early in vivo. It is thus reasonable
to suggest that inhibiting sporulation early after infection
could possibly reduce the risk of relapse due to persist-
ence of spores in the gut. Recent studies also suggest
that C. difficile can form biofilms [32,33], and it was
suggested that biofilms could possibly protect C. difficile
from antibiotics, creating an environment where sub-
MIC concentrations of antibiotics could be present [34].
In the case of fidaxomicin, high fecal concentrations,
way above the MIC, were also reported and recent
experimental data suggest that the better performance of
fidaxomicin compared to vancomycin could possibly be
due to inhibition of sporulation and toxin production, as
determined in the presence sub-MIC concentrations of
the antibiotic [20,21]. Case reports have shown that
TIGE, alone or in combination with other antibiotics,
was able to cure patients with recurrent CDI that were
refractory to MTZ and/or VAN [35,39]. The exact rea-
son why TIGE seems effective in treating recurrent CDI
remains to be elucidated and warrants further investiga-
tions, but our study suggests that the inhibition of
sporulation could be one possible explanation, like for
fidaxomicin [20].
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